StockData
Obsidian Therapeutics, Inc. logo

Obsidian Therapeutics, Inc. (OBX) stock

OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)

Close on Nov 20, 2026Market cap $741.28MP/E –Yield –

Obsidian Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$52.92M–
Q3 FY2025Sep 30, 2025-$29.63M–

More Obsidian Therapeutics figures

See a number that looks wrong?